- Home
- PMEC vs GANX Comparison
PMEC vs GANX Comparison
Compare PMEC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- GANX
- Stock Information
- Founded
- PMEC 1984
- GANX 2017
- Country
- PMEC Singapore
- GANX United States
- Employees
- PMEC N/A
- GANX N/A
- Industry
- PMEC
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- GANX Health Care
- Exchange
- PMEC Nasdaq
- GANX Nasdaq
- Market Cap
- PMEC 46.1M
- GANX 53.8M
- IPO Year
- PMEC 2023
- GANX 2021
- Fundamental
- Price
- PMEC N/A
- GANX $1.77
- Analyst Decision
- PMEC
- GANX Strong Buy
- Analyst Count
- PMEC 0
- GANX 5
- Target Price
- PMEC N/A
- GANX $8.20
- AVG Volume (30 Days)
- PMEC 52.6K
- GANX 324.3K
- Earning Date
- PMEC 01-01-0001
- GANX 08-07-2025
- Dividend Yield
- PMEC N/A
- GANX N/A
- EPS Growth
- PMEC N/A
- GANX N/A
- EPS
- PMEC N/A
- GANX N/A
- Revenue
- PMEC $74,310,000.00
- GANX N/A
- Revenue This Year
- PMEC N/A
- GANX N/A
- Revenue Next Year
- PMEC N/A
- GANX N/A
- P/E Ratio
- PMEC N/A
- GANX N/A
- Revenue Growth
- PMEC 3.94
- GANX N/A
- 52 Week Low
- PMEC $0.49
- GANX $0.89
- 52 Week High
- PMEC $1.49
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- PMEC 68.28
- GANX 44.01
- Support Level
- PMEC $1.26
- GANX $1.55
- Resistance Level
- PMEC $1.46
- GANX $2.04
- Average True Range (ATR)
- PMEC 0.12
- GANX 0.16
- MACD
- PMEC 0.03
- GANX -0.02
- Stochastic Oscillator
- PMEC 97.96
- GANX 28.34
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.